Literature DB >> 33272897

Nanobodies in cancer.

Elisha R Verhaar1, Andrew W Woodham2, Hidde L Ploegh3.   

Abstract

For treatment and diagnosis of cancer, antibodies have proven their value and now serve as a first line of therapy for certain cancers. A unique class of antibody fragments called nanobodies, derived from camelid heavy chain-only antibodies, are gaining increasing acceptance as diagnostic tools and are considered also as building blocks for chimeric antigen receptors as well as for targeted drug delivery. The small size of nanobodies (∼15 kDa), their stability, ease of manufacture and modification for diverse formats, short circulatory half-life, and high tissue penetration, coupled with excellent specificity and affinity, account for their attractiveness. Here we review applications of nanobodies in the sphere of tumor biology.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Diagnostics; Imaging; Nanobodies; VHH

Mesh:

Substances:

Year:  2020        PMID: 33272897      PMCID: PMC8164649          DOI: 10.1016/j.smim.2020.101425

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  182 in total

1.  Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.

Authors:  Maria J W D Vosjan; Jo Vercammen; Joost A Kolkman; Marijke Stigter-van Walsum; Hilde Revets; Guus A M S van Dongen
Journal:  Mol Cancer Ther       Date:  2012-02-07       Impact factor: 6.261

2.  Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.

Authors:  Tara Beers Gibson; Aarati Ranganathan; Axel Grothey
Journal:  Clin Colorectal Cancer       Date:  2006-05       Impact factor: 4.481

3.  Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo.

Authors:  Friedrich Koch-Nolte; Jan Reyelt; Britta Schössow; Nicole Schwarz; Felix Scheuplein; Stefan Rothenburg; Friedrich Haag; Vanina Alzogaray; Ana Cauerhff; Fernando A Goldbaum
Journal:  FASEB J       Date:  2007-06-15       Impact factor: 5.191

4.  Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting.

Authors:  Marina Talelli; Cristianne J F Rijcken; Sabrina Oliveira; Roy van der Meel; Paul M P van Bergen En Henegouwen; Twan Lammers; Cornelus F van Nostrum; Gert Storm; Wim E Hennink
Journal:  J Control Release       Date:  2011-01-22       Impact factor: 9.776

5.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Authors:  G Sgouros; A M Ballangrud; J G Jurcic; M R McDevitt; J L Humm; Y E Erdi; B M Mehta; R D Finn; S M Larson; D A Scheinberg
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

6.  A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.

Authors:  Fengtao You; Yinyan Wang; Licui Jiang; Xuejun Zhu; Dan Chen; Lei Yuan; Gangli An; Huimin Meng; Lin Yang
Journal:  Am J Cancer Res       Date:  2019-01-01       Impact factor: 6.166

7.  GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells.

Authors:  Julie Helft; Jan Böttcher; Probir Chakravarty; Santiago Zelenay; Jatta Huotari; Barbara U Schraml; Delphine Goubau; Caetano Reis e Sousa
Journal:  Immunity       Date:  2015-06-16       Impact factor: 31.745

8.  Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.

Authors:  R F Meredith; M B Khazaeli; W E Plott; W E Grizzle; T Liu; J Schlom; C D Russell; R H Wheeler; A F LoBuglio
Journal:  Clin Cancer Res       Date:  1996-11       Impact factor: 12.531

9.  Naturally occurring antibodies devoid of light chains.

Authors:  C Hamers-Casterman; T Atarhouch; S Muyldermans; G Robinson; C Hamers; E B Songa; N Bendahman; R Hamers
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

10.  Improved GPCR ligands from nanobody tethering.

Authors:  Ross W Cheloha; Fabian A Fischer; Andrew W Woodham; Eileen Daley; Naomi Suminski; Thomas J Gardella; Hidde L Ploegh
Journal:  Nat Commun       Date:  2020-04-29       Impact factor: 14.919

View more
  4 in total

Review 1.  Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy.

Authors:  Shuyang Sun; Ziqiang Ding; Xiaomei Yang; Xinyue Zhao; Minlong Zhao; Li Gao; Qu Chen; Shenxia Xie; Aiqun Liu; Shihua Yin; Zhiping Xu; Xiaoling Lu
Journal:  Int J Nanomedicine       Date:  2021-03-22

2.  Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells.

Authors:  Natalie Baum; Marie Eggers; Julia Koenigsdorf; Stephan Menzel; Julia Hambach; Tobias Staehler; Ralf Fliegert; Frederike Kulow; Gerhard Adam; Friedrich Haag; Peter Bannas; Friedrich Koch-Nolte
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

Review 3.  VHH Structural Modelling Approaches: A Critical Review.

Authors:  Poonam Vishwakarma; Akhila Melarkode Vattekatte; Nicolas Shinada; Julien Diharce; Carla Martins; Frédéric Cadet; Fabrice Gardebien; Catherine Etchebest; Aravindan Arun Nadaradjane; Alexandre G de Brevern
Journal:  Int J Mol Sci       Date:  2022-03-28       Impact factor: 5.923

4.  HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.

Authors:  Liqiang Li; Tianyu Liu; Linqing Shi; Xin Zhang; Xiaoyi Guo; Biao Hu; Meinan Yao; Hua Zhu; Zhi Yang; Bing Jia; Fan Wang
Journal:  Theranostics       Date:  2022-07-18       Impact factor: 11.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.